Searchable abstracts of presentations at key conferences in endocrinology

ea0049s27.1 | Vitamin D beyond bone (Endorsed by Endocrine Connections) | ECE2017

Heart & Vessels

Witte Klaus

Vitamin D is a recognised important factor in bone health but in recent years is receiving much attention for its role in multiple other systems. The enthusiasm with which it is embraced as an elixir vitae especially in cancer, cardiovascular disease and neurodegenerative diseases is overwhelming and matched only by the skepticism from other quarters, since solid evidence is largely lacking. I will review the pleiotropic effects of vitamin D and how they may be of relevance to...

ea0050p205 | Diabetes and Cardiovascular | SFEBES2017

The effect of escalating doses of beta-blockers and ACE inhibitors on mortality in patients with heart failure and diabetes mellitus

Kearney Jessica , Walker Andrew , Patel Peysh , Drozd Michael , Witte Klaus , Slater Thomas , Kearney Lorraine , Kearney Mark , Cubbon Richard

Introduction: Diabetes mellitus (DM) is a common co-morbidity in patients with heart failure and reduced left ventricular ejection fraction (HF-REF), and is associated with adverse prognosis. Subgroup analyses of randomized controlled trials suggest patients with DM benefit prognostically from beta-adrenoreceptor blockers (BB) and angiotensin converting enzyme inhibitors (ACEi). However, it remains unclear whether escalating doses of these age...

ea0050p205 | Diabetes and Cardiovascular | SFEBES2017

The effect of escalating doses of beta-blockers and ACE inhibitors on mortality in patients with heart failure and diabetes mellitus

Kearney Jessica , Walker Andrew , Patel Peysh , Drozd Michael , Witte Klaus , Slater Thomas , Kearney Lorraine , Kearney Mark , Cubbon Richard

Introduction: Diabetes mellitus (DM) is a common co-morbidity in patients with heart failure and reduced left ventricular ejection fraction (HF-REF), and is associated with adverse prognosis. Subgroup analyses of randomized controlled trials suggest patients with DM benefit prognostically from beta-adrenoreceptor blockers (BB) and angiotensin converting enzyme inhibitors (ACEi). However, it remains unclear whether escalating doses of these age...